Lite Strategy (LITS) Invested Capital (2025 - 2026)
Lite Strategy (LITS) posted Invested Capital of $56.8 million for Q1 2026, down 30.57% on a QoQ basis from $81.9 million in Q4 2025.
Analysis
Lite Strategy (LITS) Invested Capital (2025 - 2026) Analysis & Trends
Lite Strategy has reported Invested Capital for 2 years, with the latest figure at $56.8 million in Q1 2026.
- On a quarterly basis, Invested Capital changed N/A year-over-year to $56.8 million in Q1 2026; TTM through Mar 2026 was $56.8 million, a N/A change from a year earlier, with the FY2025 full-year figure at $16.9 million, changed N/A from the prior year.
- Invested Capital was $56.8 million for Q1 2026 at Lite Strategy, down from $81.9 million in the prior quarter.
- The five-year high for Invested Capital was $81.9 million in Q4 2025, with the low at $16.9 million in Q2 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Invested Cap. (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 74.44 Bn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | 40.49 Bn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 33.70 Bn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | - |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | 7.35 Bn |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | - |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | 26.94 Bn |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | - |
| 10 | Lite Strategy | 38.03 Mn | 30.49 Mn | - | 56.85 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | 56.85 Mn |
| Dec 31, 2025 | 81.88 Mn |
| Jun 30, 2025 | 16.93 Mn |